CRANBURY, N.J., June 13, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced the appointment of Ted W. Love, M.D. to its Board of Directors, effective immediately. In addition, Amicus announced that lead Independent Director, Donald J. Hayden, Jr., along with Directors Sol J. Barer, Ph.D., and James N. Topper, M.D., Ph.D, were re-elected at the 2012 Annual Meeting of Stockholders.
